Brought to you by 
Alcon licenses three of Sirion Therapeutics' eye treatments
15 May 2012
Executive Summary
Alcon has licensed US rights to fellow ophthalmic company Sirion Therapeutics' Durezol (topical difluprednate) and Zirgan (ganciclovir gel) and worldwide rights (excluding Latin America) to Zyclorin (topical cyclosporine A).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alcon licenses three of Sirion Therapeutics' eye treatments
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice